Results 301 to 310 of about 583,827 (328)

Clinical Practice Guideline: Endpoints of Resuscitation

The Journal of Trauma: Injury, Infection, and Critical Care, 2004
STATEMENT OF THE PROBLEM Severely injured trauma victims are at high risk of development of the multiple organ dysfunction syndrome (MODS) or death. To maximize chances for survival, treatment priorities must focus on resuscitation from shock (defined as inadequate tissue oxygenation to meet tissue O2 requirements), including appropriate fluid ...
Samuel A, Tisherman, Philip, Barie, Faran, Bokhari, John, Bonadies, Brian, Daley, Lawrence, Diebel, Soumitra R, Eachempati, Stanley, Kurek, Fred, Luchette, Juan, Carlos Puyana, Martin, Schreiber, Ronald, Simon   +11 more
openaire   +2 more sources

Aspirin Resistance: Focus on Clinical Endpoints

Journal of Cardiovascular Pharmacology, 2008
Via its antiplatelet effect, aspirin reduces the odds of an arterial thrombotic event in high-risk patients by approximately 25%. However, 10% to 20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term follow-up.
Pusch, Gabriella, Fehér, Gergely, Kótai, Katalin, Tibold, Antal, Gasztonyi, Beáta, Fehér, Andrea, Papp, Előd, Lupkovics, Géza, Szapáry, László   +8 more
openaire   +3 more sources

Clinical trials: surrogate endpoints or hard endpoints?

The American Journal of Cardiology, 2001
A man, aged 50, has about a 50% risk and a 50-year-old woman a 35% risk of having a myocardial infarction during their lifetime. The extent of atherosclerosis is the primary determinant of the risk of myocardial infarction. We will be unable to substantially reduce the lifetime risk of coronary artery disease without primary prevention of ...
openaire   +2 more sources

Endpoint considerations for clinical trials

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2002
(2002). Endpoint considerations for clinical trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Vol. 3, No. sup1, pp. S3-S6.
openaire   +2 more sources

Surrogate Endpoints of Clinical Benefit

2012
Despite several decades of intensive clinical and biological research and significant progress in primary prevention, screening, diagnosis, prognosis, and treatment, cancer is still the second most common cause of death in developed countries, accounting for about one-fourth of total deaths [1].
G. Ciccone, BALDI, ILEANA
openaire   +2 more sources

Demonstrating bioequivalence using clinical endpoint studies

Journal of Veterinary Pharmacology and Therapeutics, 2012
Bermingham, E., del Castillo, J. R. E., Lainesse, C., Pasloske, K., Radecki, S. Demonstrating bioequivalence using clinical endpoint studies. J. vet. Pharmacol. Therap.35 (Suppl. 1), 31–37.For drug products not amenable to blood level studies, clinical endpoint studies have been used as an indirect measure of formulation difference in bioavailability ...
E, Bermingham, J R E, Del Castillo, C, Lainesse, K, Pasloske, S, Radecki   +4 more
openaire   +2 more sources

Surrogate endpoints in clinical trials: Cancer

Statistics in Medicine, 1989
AbstractInvestigators use a surrogate endpoint when the endpoint of interest is too difficult and/or expensive to measure routinely and when they can define some other, more readily measurable, endpoint, that is sufficiently well correlated with the first to justify its use as a substitute.
S, Ellenberg, J M, Hamilton
openaire   +2 more sources

Clinical trial designs and endpoints

Trials should be designed with consideration of the individual disease context and research question. Many different approaches may be justified. In this chapter, we therefore consider some of the principal components of trial design in general and within the context of the emerging field of gene and cell therapies.
Marie-Louise, Zeissler, Rebecca, Chapman
openaire   +2 more sources

Endpoints in prostate cancer clinical trials

Urology, 2002
Prostate cancer is an extraordinarily heterogeneous disease with a variety of prognostic factors influential in determining ultimate patient outcomes. However, the vast majority of men harboring pathologic evidence of prostate cancer are not clinically diagnosed with this disease.
openaire   +2 more sources

Death: The Simple Clinical Trial Endpoint

2019
Death, as a biological phenomenon, is well understood and a commonly employed endpoint for clinical trials. However, death identification and adjudication may be difficult for pragmatic clinical trials (PCT) that rely upon electronic health record and patient reported data. We propose a novel death identification and verification approach that is being
Eric L, Eisenstein, Kristi, Prather, Stephen J, Greene, Tina, Harding, Amanda, Harrington, Davera, Gabriel, Ingrid, Jones, Robert J, Mentz, Eric J, Velazquez, Kevin J, Anstrom   +9 more
openaire   +2 more sources